Valeant Pharmaceuticals

Latest articles

3d
Boston Globe
Finally, more drug trial results are being made public— one year following a trial’s completion or termination — and there were notab
Boston Globe / Posted 3 days ago
— one year following a trial’s completion or termination — and there were notable exceptions to the overall trend. Valeant Pharmaceuticals, Albert Einstein School of Medicine, the University of Nebraska, and the University of California... Read more
15d
FOX Business
Pershing Square, Valeant to appear in court on insider trading suit settlementA U.S. court on Tuesday asked Valeant Pharmaceuticals International and activis
FOX Business / Posted 15 days ago
A U.S. court on Tuesday asked Valeant Pharmaceuticals International and activist investor Bill Ackman's Pershing Square to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit. The hearing, set for Jan. 16, comes... Read more
2 related articles
15d
FOX Business
Pershing Square, Valeant to appear in court on insider trading suit settlementA U.S. court on Tuesday asked Valeant Pharmaceuticals International and activis
FOX Business / Posted 15 days ago
A U.S. court on Tuesday asked Valeant Pharmaceuticals International and activist investor Bill Ackman's Pershing Square to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit. Continue Reading Below The hearing,... Read more
2 related articles
15d
Channel NewsAsia
Pershing Square, Valeant asked to appear for hearing on insider trading suitREUTERS: A U.S. court on Tuesday asked Valeant Pharmaceuticals International In
Channel NewsAsia / Posted 15 days ago
REUTERS: A U.S. court on Tuesday asked Valeant Pharmaceuticals International Inc and activist investor Bill Ackman's Pershing Square to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit. The hearing, set for Jan.... Read more
2 related articles
15d
Inquirier.net
Top Canadian CEOs made more than 200 times average worker — studymeanwhile the highest paid among them were raking in record-breaking earnings,”
Inquirier.net / Posted 15 days ago
meanwhile the highest paid among them were raking in record-breaking earnings,” said the report’s author, David Macdonald. Valeant Pharmaceuticals’ CEO Joseph Papa was the best paid in 2016, making Can$83.1 million in eight months on the job,... Read more
16d
CBC.ca
Canada's top CEOs will earn your annual salary before lunch today, says reportThe lion's share came from share grants (33 per cent), bonuses (26 per cent) an
CBC.ca / Posted 16 days ago
The lion's share came from share grants (33 per cent), bonuses (26 per cent) and stock options (15 per cent). For 2016, Valeant Pharmaceuticals CEO Joseph Papa scored the top spot, earning more than $83 million in total compensation. Almost $56... Read more
17d
FOX Business
3 Top Value Stocks to Buy in 2018version of the story is that Horizon originally decided to closely emulate the
FOX Business / Posted 17 days ago
version of the story is that Horizon originally decided to closely emulate the failed business model of serial acquirer Valeant Pharmaceuticals International. When Valeant's stock collapsed because of its controversial pricing practices and... Read more
17d
FOX Business
3 Top Value Stocks to Buy in 2018version of the story is that Horizon originally decided to closely emulate the
FOX Business / Posted 17 days ago
version of the story is that Horizon originally decided to closely emulate the failed business model of serial acquirer Valeant Pharmaceuticals International. When Valeant's stock collapsed because of its controversial pricing practices and... Read more
19d
Business Insider
Bill Ackman just took a $200 million hit to his reputationThe billionaire investor Bill Ackman and his firm, Pershing Square — along with
Business Insider / Posted 19 days ago
The billionaire investor Bill Ackman and his firm, Pershing Square — along with Valeant Pharmaceuticals — will pay just under $300 million to settle an insider-trading suit over their attempt to buy the pharmaceutical firm Allergan in 2014. Ackman... Read more
3 related articles
19d
Stamford Advocate
Bill Ackman just took a $200 million hit to his reputationBillionaire investor Bill Ackman and his firm Pershing Square, along with Valea
Stamford Advocate / Posted 19 days ago
Billionaire investor Bill Ackman and his firm Pershing Square, along with Valeant Pharmaceuticals, will pay just under $300 million to settle an insider-trading suit over their attempt to buy pharmaceutical firm Allergan in 2014. Ackman will pay the... Read more
3 related articles
19d
Connecticut Post
Bill Ackman just took a $200 million hit to his reputationBillionaire investor Bill Ackman and his firm Pershing Square, along with Valea
Connecticut Post / Posted 19 days ago
Billionaire investor Bill Ackman and his firm Pershing Square, along with Valeant Pharmaceuticals, will pay just under $300 million to settle an insider-trading suit over their attempt to buy pharmaceutical firm Allergan in 2014. Ackman will pay the... Read more
3 related articles
19d
Channel NewsAsia
Pershing Square, Valeant arrive at settlement split for Allergan lawsuitREUTERS: Activist investor William Ackman's Pershing Square and Valeant Pharmac
Channel NewsAsia / Posted 19 days ago
REUTERS: Activist investor William Ackman's Pershing Square and Valeant Pharmaceuticals on Friday decided to pay US$290 million to settle a lawsuit that accused them of insider trading before bidding for Allergan Plc in 2014. Pershing Square said it... Read more
3 related articles
30d
Channel NewsAsia
Aerie's glaucoma treatment gets early FDA approvalan advisory panel to the drug regulator had voted 9-1 in favor of Rhopressa's a
Channel NewsAsia / Posted 30 days ago
an advisory panel to the drug regulator had voted 9-1 in favor of Rhopressa's approval. Rhopressa's approval followed Valeant Pharmaceuticals International Inc's announcement on Monday that it would begin shipping to U.S. wholesalers its... Read more
30d
Profit Confidential
Don’t Sweat the Downgrade, Valeant Stock Remains BullishValeant Stock Remains Bullish Patrick Brik CFA, BAS Profit Confidential 2017
Profit Confidential / Posted 30 days ago
Valeant Stock Remains Bullish Patrick Brik CFA, BAS Profit Confidential 2017-12-18T11:37:40Z 2017-12-18 11:37:40 valeant pharmaceuticals intl incnyse:vrxvaleant stockvrx stockvrx stock chartvaleant stock pricevaleant stock chartvaleant... Read more
5 related articles
m
FOX Business
Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Todaysome bad news from individual companies spoiled the market's previously positiv
FOX Business / Posted 1 months ago
some bad news from individual companies spoiled the market's previously positive tone. Sanderson Farms (NASDAQ: SAFM), Valeant Pharmaceuticals International (NYSE: VRX), and Criteo (NASDAQ: CRTO) were among the worst performers on the day.... Read more
m
FOX Business
Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Todaysome bad news from individual companies spoiled the market's previously positiv
FOX Business / Posted 1 months ago
some bad news from individual companies spoiled the market's previously positive tone. Sanderson Farms (NASDAQ: SAFM), Valeant Pharmaceuticals International (NYSE: VRX), and Criteo (NASDAQ: CRTO) were among the worst performers on the day.... Read more
m
FOX Business
Here's What's Behind Valeant Pharmaceuticals' 13% DropShares of Valeant Pharmaceuticals(NYSE: VRX), the embattled drugmaker that's pr
FOX Business / Posted 1 months ago
Shares of Valeant Pharmaceuticals(NYSE: VRX), the embattled drugmaker that's primarily grown through price hikes and acquisitions this decade, tumbled as much as 13% on Thursday after receiving a premarket rating downgrade from J.P. Morgan... Read more
m
FOX Business
Here's What's Behind Valeant Pharmaceuticals' 13% DropContinue Reading Below Shares of Valeant Pharmaceuticals(NYSE: VRX), the embat
FOX Business / Posted 1 months ago
Continue Reading Below Shares of Valeant Pharmaceuticals(NYSE: VRX), the embattled drugmaker that's primarily grown through price hikes and acquisitions this decade, tumbled as much as 13% on Thursday after receiving a premarket rating downgrade... Read more

In this news